Effect of Chitosan oligosaccharides on ischemic symptom and gut microbiota disbalance in mice with hindlimb ischemia

Zhu, Lin; Hu, Baifei; Guo, Yanlei; Yang, Huabing; Zheng, Junping; Hu, Haiming; Liu, Hongtao

doi:10.1016/j.carbpol.2020.116271

Cited by 11 publications

(10 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zhou et al reported that orally administrated heparin was mainly distributed in the gastrointestinal tract of mice and was structurally stable in simulated gastric and intestinal fluids in vitro [43]. Our results indicate that clam heparinoids regulate the structure of intestinal flora, which is consistent with the results of Shang et al [44] and Zhu et al [45]. However, clam heparinoids had no specific function to promote beneficial bacteria, inhibit harmful bacteria, and regulate diversity, which may be caused by host specificity, model type, amount and type of polysaccharide, and interaction time [44,[46][47][48].…”

Section: Discussionsupporting

confidence: 92%

Antithrombotic Activity of Heparinoid G2 and Its Derivatives from the Clam Coelomactra antiquata

et al. 2022

View full text Add to dashboard Cite

Clam heparinoid G2 (60.25 kDa) and its depolymerized derivatives DG1 (24.48 kDa) and DG2 (6.75 kDa) prepared from Coelomactra antiquata have been documented to have excellent fibrinolytic and anticoagulant activity. In this study, to further explore the antithrombotic activity of G2, DG1 and DG2, azure A, sheep plasma, and clot lytic rate assays were used to determine their anticoagulant and thrombolytic activity in vitro. The results indicated that the anticoagulant titer of G2 was approximately 70% that of heparin and the thrombolytic activity of DG2 was greater than G2, DG1, and heparin activities. Moreover, in a carrageenan-induced venous thrombosis model, oral administration of G2 and DG1 each at 20 mg/kg and 40 mg/kg for 7 days significantly reduced blacktail thrombus formation, increased tissue-type plasminogen activator, fibrin degradation products, and D-dimer levels, decreased von Willebrand factor and thromboxane B2 levels, and restored phylum and genus abundance changes of intestinal bacteria. DG2 had no antithrombotic effect. At 20 mg/kg, G2, DG1, and heparin had comparable antithrombotic activities, and DG1 at 40 mg/kg had more muscular antithrombotic activity than G2. Thus, DG1 could be an antithrombotic oral agent owing to its more robust antithrombotic activity and lower molecular weight.

show abstract

Section: Discussionsupporting

confidence: 92%

Antithrombotic Activity of Heparinoid G2 and Its Derivatives from the Clam Coelomactra antiquata

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Chitosan oligosaccharides do not show any toxic influence after oral administration to rats at doses ranging from 500 to 2000 mg/kg/day for 28 days . Several studies reported that COS dose in the animal experiment model varies from 200 to 1500 mg/kg, − as well as the clinical significance of the doses used, COS at a dose level of 200, 500, and 1000 mg/kg were obtained in this study. The 1000 mg/kg lactose dose was calculated, based on the allometric formula of the human equivalent dose (HED), considering an average daily human consumption of 166 mg/kg (the dose of 166 mg/kg/day in a 60 kg adult, corresponds to the consumption of 10 g/day): Rat dose (mg/kg/day) = human dose (mg/kg/day) × (human K m */rat K m *). Rat dose (mg/kg/day) = 166 × (37/6) =1000 mg/kg/day. …”

Section: Methodssupporting

confidence: 63%

Ameliorative Effect of Chitosan Oligosaccharides on Hepatic Encephalopathy by Reshaping Gut Microbiota and Gut–Liver Axis

Wang

et al. 2022

J. Agric. Food Chem.

View full text Add to dashboard Cite

This study investigated the influence of chitosan oligosaccharides (COSs) on a thioacetamide-induced hepatic encephalopathy (HE) Wistar rat model. COS treatment statistically reduced the false neurotransmitters and blood ammonia in HE rats, along with the suppression of oxidative stress and inflammation. The disbalanced gut microbiota was detected in HE rats by 16S rDNA sequencing, but the abundance alterations of some intestinal bacteria at either the phylum or genus level were at least partly restored by COS treatment. According to metabolomics analysis of rat feces, six metabolism pathways with the greatest response to HE were screened, several of which were remarkably reversed by COS. The altered metabolites might serve as a bridge for the alleviated HE rats treated with COS and the enhanced intestinal bacterial structure. This study provides novel guidance to develop novel food or dietary supplements to improve HE diseases due to the potential beneficial effect of COS on gut–liver axis.

show abstract

“…The dose of PCO was based on our previous studies of other oligosaccharides. 20,23 Both diets with the same energy were purchased from Keao Xieli Co., Ltd (Beijing, China). The compositions of NCD and HFD in our experiment are listed in ESI Table 1 †.…”

Section: Methodsmentioning

confidence: 99%

Structural characterization ofPoria cocosoligosaccharides and their effects on the hepatic metabolome in high-fat diet-fed mice

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

Effect of Chitosan oligosaccharides on ischemic symptom and gut microbiota disbalance in mice with hindlimb ischemia

Cited by 11 publications

References 53 publications

Antithrombotic Activity of Heparinoid G2 and Its Derivatives from the Clam Coelomactra antiquata

Antithrombotic Activity of Heparinoid G2 and Its Derivatives from the Clam Coelomactra antiquata

Ameliorative Effect of Chitosan Oligosaccharides on Hepatic Encephalopathy by Reshaping Gut Microbiota and Gut–Liver Axis

Structural characterization ofPoria cocosoligosaccharides and their effects on the hepatic metabolome in high-fat diet-fed mice

Contact Info

Product

Resources

About